A retrospective, multicentre, longitudinal cohort study of vismodegib for the treatment of locally advanced Basal cell carcinoma (laBCC), metastatic Basal cell carcinoma (mBCC), multiple Basal cell carcinomas in basal cell nevus syndrome (BCNS), and in non-BCNS patients patients in the Netherlands.
Latest Information Update: 28 Jan 2021
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer; Basal cell nevus syndrome; Carcinoma; Xeroderma pigmentosum
- Focus Therapeutic Use
- 28 Jan 2021 New trial record
- 19 Jan 2021 Results published in the British Journal of Cancer